{"id":"guanoxabenz","rwe":[{"pmid":"25045021","year":"2014","title":"The mitochondrial amidoxime reducing component (mARC): involvement in metabolic reduction of N-oxides, oximes and N-hydroxyamidinohydrazones.","finding":"","journal":"ChemMedChem","studyType":"Clinical Study"},{"pmid":"19053771","year":"2008","title":"The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.","finding":"","journal":"Journal of medicinal chemistry","studyType":"Clinical Study"},{"pmid":"16118330","year":"2005","title":"Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid).","finding":"","journal":"Drug metabolism and disposition: the biological fate of chemicals","studyType":"Clinical Study"},{"pmid":"9820876","year":"1998","title":"Characterization of guanoxabenz reducing activity in rat brain.","finding":"","journal":"Pharmacology & toxicology","studyType":"Clinical Study"},{"pmid":"9802321","year":"1998","title":"Characterization of the enzymatic activity for biphasic competition by guanoxabenz (1-(2,6-dichlorobenzylidene-amino)-3-hydroxyguanidine) at alpha2-adrenoceptors. II. Description of a xanthine-dependent enzymatic activity in spleen cytosol.","finding":"","journal":"Biochemical pharmacology","studyType":"Clinical Study"}],"tags":[{"label":"guanoxabenz","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C02CC07","category":"atc"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"hydroxyguanabenz","offLabel":[],"synonyms":["guanoxabenz","hydroxyguanabenz","guanoxabenz hydrochloride"],"timeline":[],"approvals":[],"brandName":"Hydroxyguanabenz","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"guanoxabenz","explanation":"Think of neurotransmitters like messengers that help different parts of the brain talk to each other. Hydroxyguanabenz is thought to help regulate the activity of these messengers, which can help to calm or stimulate different brain regions as needed. This can potentially help to treat a range of conditions, but more research is needed to understand its exact effects.","oneSentence":"Hydroxyguanabenz is believed to work by modulating certain neurotransmitter systems in the brain.","technicalDetail":"The exact mechanism of action of hydroxyguanabenz is unknown, but it is believed to interact with certain neurotransmitter receptors and transporters in the brain, potentially influencing the activity of dopamine, norepinephrine, and other neurotransmitters."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1345","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GUANOXABENZ","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:50:21.214795","biosimilars":[],"competitors":[{"drugName":"betanidine","drugSlug":"betanidine","fdaApproval":"","relationship":"same-class"},{"drugName":"guanethidine","drugSlug":"guanethidine","fdaApproval":"1960-07-05","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"guanoxabenz","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"betanidine","brandName":"betanidine","genericName":"betanidine","approvalYear":"","relationship":"same-class"},{"drugId":"guanethidine","brandName":"guanethidine","genericName":"guanethidine","approvalYear":"1960","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"P9HIK5V7WK","CHEBI":"CHEBI:135006","INN_ID":"3615","UMLSCUI":"C0061990","ChEMBL_ID":"CHEMBL461343","KEGG_DRUG":"D04398","DRUGBANK_ID":"DB13410","PUBCHEM_CID":"9567831","SECONDARY_CAS_RN":"23256-40-8","MESH_SUPPLEMENTAL_RECORD_UI":"C028782"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":31,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"C02CC07","allCodes":["C02CC07"]},"biosimilarFilings":[],"recentPublications":[{"date":"2014 Oct","pmid":"25045021","title":"The mitochondrial amidoxime reducing component (mARC): involvement in metabolic reduction of N-oxides, oximes and N-hydroxyamidinohydrazones.","journal":"ChemMedChem"},{"date":"2008 Dec 25","pmid":"19053771","title":"The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.","journal":"Journal of medicinal chemistry"},{"date":"2005 Nov","pmid":"16118330","title":"Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid).","journal":"Drug metabolism and disposition: the biological fate of chemicals"},{"date":"1998 Oct","pmid":"9820876","title":"Characterization of guanoxabenz reducing activity in rat brain.","journal":"Pharmacology & toxicology"},{"date":"1998 Nov 1","pmid":"9802321","title":"Characterization of the enzymatic activity for biphasic competition by guanoxabenz (1-(2,6-dichlorobenzylidene-amino)-3-hydroxyguanidine) at alpha2-adrenoceptors. II. Description of a xanthine-dependent enzymatic activity in spleen cytosol.","journal":"Biochemical pharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxyguanabenz, also known as GUANOXABENZ, is a small molecule drug in the guanoxabenz class. Its exact target and mechanism of action are unknown, but it is believed to work by modulating certain neurotransmitter systems in the brain. Hydroxyguanabenz is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are also unknown. Further research is needed to fully understand its potential therapeutic applications and safety profile. As a result, it is not currently available for clinical use.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}